Shares of Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) hit a new 52-week high during trading on Friday . The stock traded as high as $22.28 and last traded at $22.28, with a volume of 6414 shares traded. The stock had previously closed at $20.20.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. initiated coverage on shares of Ascentage Pharma Group International in a research report on Thursday. They set an “overweight” rating for the company.
Read Our Latest Stock Analysis on AAPG
Ascentage Pharma Group International Stock Performance
About Ascentage Pharma Group International
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
- Five stocks we like better than Ascentage Pharma Group International
- How to Start Investing in Real Estate
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- How to Use Stock Screeners to Find Stocks
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
- Want to Profit on the Downtrend? Downtrends, Explained.
- Ibotta Stock: Why the Buyback Looks Like a Bullish Bet
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
